BIRMINGHAM, Ala. and NAPLES, Fla. , Sept. 16, 2022 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) and NCH Healthcare System announce the opening of Encompass Health Rehabilitation Hospital of Naples , a 50-bed inpatient rehabilitation hospital located at 14305 Collier Blvd. The hospital serves patients recovering from debilitating illnesses and injuries including strokes and other neurological disorders, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions.
In addition to 24-hour nursing care, Encompass Health Rehabilitation Hospital of Naples offers physical, occupational and speech therapies to restore functional ability and quality of life. Care is provided by highly specialized nurses, therapists and physicians. The hospital features all private patient rooms, a large therapy gym with advanced rehabilitation technologies and an activities of daily living suite, a therapy courtyard, a cafeteria and a dayroom.
"We are excited to open this new hospital in Naples to help individuals recovering from major illnesses and injuries regain the strength and function to return to the community at their highest levels of independence," said Enid Gonzalez , CEO of Encompass Health of Naples . "Every detail of the hospital was created with our patients in mind – our freestanding, one-story hospital allows for easier transfers from other facilities and more convenient access for families and visitors. This hospital will give members of the community more options, closer to home for intensive rehabilitation services."
"NCH Healthcare System is in a period of transformational change becoming an advanced community healthcare system," said Paul Hiltz , President & CEO, NCH Healthcare System. "This collaboration with Encompass Health will allow more patients in our community in need of specialized rehabilitative care to get it right here in Naples ."
Encompass Health Rehabilitation Hospital of Naples is Encompass Health's 153rd inpatient rehabilitation hospital and its 19th inpatient rehabilitation hospital in Florida .
About NCH Healthcare System The NCH Healthcare System is a not-for-profit, multi-facility healthcare system located in Naples, Florida , and is a member of the Mayo Clinic Care Network. The System is more than just two hospitals (referred to as the NCH Baker Hospital and NCH North Naples Hospital) with a total of 713 beds. NCH is an alliance of 775 physicians and medical facilities in dozens of locations throughout Collier County and southwest Florida that offers nationally recognized, quality health care to our community. NCH delivers 3,500 babies and houses the only pediatric ER in Collier County serving more than 19,000 children every year. We take pride in caring for the next generation of leaders. Our mission is to help everyone live a longer, happier, healthier life. For more information, visit www.NCHmd.org.
About Encompass Health Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States . With a national footprint that includes 153 hospitals in 36 states and Puerto Rico , the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
FORWARD-LOOKING STATEMENT Statements contained in this press release which are not historical facts, such as those relating to the likelihood, timing and effects of the opening of the jointly owned hospital, are forward-looking statements. In addition, Encompass Health may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Encompass Health's actual results or events may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual results or events to differ materially from those anticipated include, but are not limited to, any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings that may be brought by or against Encompass Health or NCH Healthcare System; the continued spread of COVID-19, including the speed, geographic reach and duration of the spread; the actions to be taken by Encompass Health or NCH Healthcare System in response to the COVID-19 pandemic; changes in the regulation of the healthcare industry at either or both of the federal and state levels; competitive pressures in the healthcare industry and Encompass Health's response thereto; the hospital's ability to maintain proper local, state and federal licensing; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or NCH Healthcare System's information systems; the ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on labor expenses from potential union activity and staffing shortages; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; general conditions in the economy and capital markets; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10-K for the year ended Dec. 31, 2021 and Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 .
Encompass Health contacts: Media contact: Danielle Hall | 205-970-5912 danielle.hall@encompasshealth.com
Investor Relations contact: Mark Miller | 205-970-5860 mark.miller@encompasshealth.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/encompass-health-rehabilitation-hospital-of-naples-a-50-bed-inpatient-rehabilitation-hospital-now-open-301626472.html
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.
In a recent interview with PEOPLE, the couple, whose real-life love story was portrayed in The Big Sick, opened up about what it's like to be in the immunocompromised community
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC). Eli Lilly seems to excel in both areas. Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.
A labor shortage at a pharmaceutical company along with increased demand left Adderall on back-order at many pharmacies across the country.
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
Intellia Therapeutics said two of its experimental Crispr treatments produced positive results in early-stage trials.
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.
As the bear market emerged, even some of the healthiest companies saw their shares drop or stagnate. Shares of Axsome Therapeutics (NASDAQ: AXSM) have climbed 64% this year. Most of the gains came in recent weeks after the company's great news: It won U.S. regulatory approval for Auvelity, its drug for major depressive disorder (MDD).
A surgery to remove the problem tissue went "extremely well," her doctor said.
How do you fix a forgetful memory? Neurologist shares brain exercises to keep memory sharp, including reading fiction, cooking from recipes and playing games.
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
In June, a Dallas area doctor who was feeling unwell wanted to use a saline IV bag she had gotten from her work to try to rehydrate. She tapped it into her veins while at home. Minutes later, she suffered a major medical event and died, court records say. Now, Raynaldo Rivera Ortiz Jr., an anesthesiologist at her surgical facility, faces federal charges for allegedly tampering with IV bags in a way that resulted in the death of his colleague as well as several other cardiac emergencies, accordin
“The safety of the nation’s pharmaceutical supply is critically important,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division
Lawmakers hear from scientists about advancements to slow down the aging process
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.